Nonalcoholic steatohepatitis (NASH) is fast becoming the leading cause of liver failure today. As the worldwide prevalence of obesity and type 2 diabetes (T2D) increases, so do the complications of NASH.

As pharmaceutical pipelines swell with product candidates seeking a NASH indication, Chiltern provides the strategic and logistical development expertise that sponsors need.

Today, the typical Phase II or III NASH study protocol incorporates a primary endpoint of a threefold improvement in inflammation without worsening of fibrosis (or vice versa) for the active treatment vs. placebo. While such an endpoint makes a NASH clinical development program far faster and less costly than one in T2D, it still represents a major, long-term investment.

Nonalcoholic steatohepatitis (NASH) is fast becoming the leading cause of liver failure today. As the worldwide prevalence of obesity and type 2 diabetes (T2D) increases, so do the complications of NASH.

As pharmaceutical pipelines swell with product candidates seeking a NASH indication, Chiltern provides the strategic and logistical development expertise that sponsors need.

Today, the typical Phase II or III NASH study protocol incorporates a primary endpoint of a threefold improvement in inflammation without worsening of fibrosis (or vice versa) for the active treatment vs. placebo. While such an endpoint makes a NASH clinical development program far faster and less costly than one in T2D, it still represents a major, long-term investment.
MULTIPARAMETER MRI AS ALTERNATIVE TO LIVER BIOPSY

Chiltern has found that the use of well-vetted, noninvasive biomarkers, with their greater sensitivity and specificity for NASH and/or advanced fibrosis, can reduce biopsy screen failure rates from 70% to 50% or less.

In particular, using MRI to analyze multiparameter biomarkers confers several advantages over biopsy screening, including:

• Greater patient acceptance of multiple MRI scans
• Considerably lower costs, less time and improved patient safety
• The ability to assess disease burden over the entire liver
• Computerized image analysis, enabling more objective scoring of nonalcoholic fatty liver disease (NAFLD) severity
• Scoring of inflammation and fibrosis over full range of NAFLD severity

HOW WE HELP

Chiltern has a presence in 47 countries and a staff of more than 4,300 people, many of whom hold advanced degrees. We are large enough to handle your trials worldwide, and have decades of experience working with the world’s most influential drug and device developers. Chiltern’s experienced team of gastroenterology and hepatology trial design and logistics specialists can enhance the value and efficiency of your clinical development program. Whether you are in planning mode or ready to start trials, let’s talk about how we can apply our medical, scientific, operational and regulatory talents to further your product success.

RANDY L. ANDERSON, Ph.D.
Senior Vice President, Scientific and Regulatory Affairs
Therapeutic Area Leader for Endocrinology and Metabolism

Dr. Randy Anderson is a statistical scientist specializing in the design, oversight, analytical interpretation and reporting of prospective clinical trials. His expertise in NAFLD (of which NASH is a subset), a disease with complications similar to those of diabetes, makes him highly qualified to manage and support clinical development programs in this area.